Literature DB >> 23713827

Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors.

Arnd Heiligenhaus1, Carsten Heinz, Clive Edelsten, Kaisu Kotaniemi, Kirsten Minden.   

Abstract

Juvenile idiopathic arthritis (JIA) is the most common systemic disease associated with uveitis in childhood. The frequency of JIA-associated uveitis (JIAU) varies geographically, and between ethnicities. Uveitis risk is high in JIA associated with oligoarthritis, young age at arthritis onset and ANA positivity. Gender alters risk for the incidence of JIA and the severity of JIAU. Familial cases support the possible role of genetic influences in the pathogenesis. Arthritis typically precedes the uveitis, but uveitis may occur up to seven years following the arthritis onset. Although complications still occur, the frequency of bilateral blindness has dropped, probably by both improved screening of high-risk patients with JIA, and the increased use of early immunosuppression. However, there is still continuing persistence of JIAU into adulthood. For improvement of epidemiological knowledge of this complicated disease, large, well-defined, long-term population-based registries are needed with the application of universally agreed case definitions and outcome measures.

Entities:  

Mesh:

Year:  2013        PMID: 23713827     DOI: 10.3109/09273948.2013.791701

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  45 in total

Review 1.  Uveitis in juvenile idiopathic arthritis.

Authors:  Arnd Heiligenhaus; Kirsten Minden; Dirk Föll; Uwe Pleyer
Journal:  Dtsch Arztebl Int       Date:  2015-02-06       Impact factor: 5.594

2.  Juvenile idiopathic arthritis in the biologic era: predictors of the disease progression and need for early introduction of biologic treatment.

Authors:  Panayiota Nalbanti; Florentia Kanakoudi-Tsakalidou; Maria Trachana; Polyxeni Pratsidou-Gertsi; Evangelia Farmaki; Panagiotis Bamidis; Fotios Papachristou
Journal:  Rheumatol Int       Date:  2018-05-29       Impact factor: 2.631

Review 3.  The role of sex in uveitis and ocular inflammation.

Authors:  Ian Y L Yeung; Nicholas A Popp; Chi-Chao Chan
Journal:  Int Ophthalmol Clin       Date:  2015

Review 4.  Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?

Authors:  Heinrike Schmeling; Gerd Horneff; Susanne M Benseler; Marvin J Fritzler
Journal:  Nat Rev Rheumatol       Date:  2014-08-12       Impact factor: 20.543

Review 5.  Gender disparities in ocular inflammatory disorders.

Authors:  Hatice Nida Sen; Janet Davis; Didar Ucar; Austin Fox; Chi Chao Chan; Debra A Goldstein
Journal:  Curr Eye Res       Date:  2014-07-02       Impact factor: 2.424

Review 6.  Uveitis associated with juvenile idiopathic arthritis.

Authors:  Ethan S Sen; Andrew D Dick; Athimalaipet V Ramanan
Journal:  Nat Rev Rheumatol       Date:  2015-03-31       Impact factor: 20.543

7.  Frequency of joint involvement in juvenile idiopathic arthritis during a 5-year follow-up of newly diagnosed patients: implications for MR imaging as outcome measure.

Authors:  Robert Hemke; Charlotte M Nusman; Désirée M F M van der Heijde; Andrea S Doria; Taco W Kuijpers; Mario Maas; Marion A J van Rossum
Journal:  Rheumatol Int       Date:  2014-08-14       Impact factor: 2.631

8.  [Uveitis in juvenile idiopathic arthritis].

Authors:  I Foeldvari; K Walscheid; A Heiligenhaus
Journal:  Z Rheumatol       Date:  2017-10       Impact factor: 1.372

9.  Autoimmune response to transthyretin in juvenile idiopathic arthritis.

Authors:  Cristina C Clement; Halima Moncrieffe; Aditi Lele; Ginger Janow; Aniuska Becerra; Francesco Bauli; Fawzy A Saad; Giorgio Perino; Cristina Montagna; Neil Cobelli; John Hardin; Lawrence J Stern; Norman Ilowite; Steven A Porcelli; Laura Santambrogio
Journal:  JCI Insight       Date:  2016-02-25

Review 10.  Ocular Involvement in Juvenile Idiopathic Arthritis: Classification and Treatment.

Authors:  Ivan Foeldvari
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.